SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
• | Event: Stifel 2024 Healthcare Conference |
Location: New York, NY | |
Date: Monday, November 18, 2024 | |
Time: 4:10-4:40 PM ET | |
• | Event: Jefferies London Healthcare Conference |
Location: London, UK | |
Date: Wednesday, November 20, 2024 | |
Time: 8:00-8:25 AM GMT | |
• | Event: Piper Sandler Healthcare Conference |
Location: New York, NY | |
Date: Wednesday, December 4, 2024 | |
Time: 4:00-4:25 PM ET |
A webcast of the presentations will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of each event for thirty days.
About Ventyx Biosciences
Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical needs with novel oral therapies that can shift inflammation and immunology markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting NLRP3, S1P1R and TYK2, positioning us to become a leader in the development of oral immunology therapies for peripheral and neuroinflammatory diseases. Ventyx is headquartered in San Diego, California. For more information about Ventyx, please visit www.ventyxbio.com.
Investor Relations Contact
Joyce Allaire
Managing Director
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.85 |
Daily Change: | 0.12 6.94 |
Daily Volume: | 2,139,247 |
Market Cap: | US$130.740M |
November 07, 2024 October 15, 2024 September 23, 2024 September 06, 2024 August 08, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB